AbCellera
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Canada · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
2215 Yukon St, Vancouver, British Columb...Phone Number
(604) 559-9005Website
www.abcellera.comRevenue
$79.2 MillionStock Symbol
ABCLIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
4
1
1
About AbCellera
AbCellera is a biotechnology company based in Vancouver, Canada, specializing in antibody discovery and development. Their proprietary technology platform leverages single-cell screening, machine learning, and high-throughput genomics to identify and develop therapeutic antibodies. AbCellera collaborates with pharmaceutical and biotechnology companies to accelerate the development of antibody-based medicines across various therapeutic areas, including oncology, autoimmune diseases, and infectious diseases.Explore more
AbCellera Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AbCellera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
AbCellera, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if AbCellera had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at AbCellera
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on AbCellera recently announced quarterly report
Funding: Get notified immidiatlly once AbCellera has new funding data
Check out if AbCellera is spiking on competitors!
Check if AbCellera has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when AbCellera launches new products
Recommended Actions
Reach out to Masked Content who joined AbCellera as Masked Content
Find 3 more new buyers
Compare Similar Companies to AbCellera
Compare insights from companies similar to AbCellera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AbCellera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AbCellera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AbCellera.
AbCellera financials insights
Gather financial insights about AbCellera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$10M
2020
Series B
$105M
Stock Offering
$483M
2021
Stock Offering
$288.5M
AbCellera Tech Stack
A closer look at the technologies used by AbCellera
See more technologies
Most Recent Scoops
Person-Based
Earnings, Compliance, Finance
Project
AbCellera has outlined a differentiation thesis for ABCL-635 versus approved small molecules, noting that as a human monoclonal antibody it is not expected to produce the liver toxicity or somnolence associated with fezolinetant and elinzanetant, with a target product profile of a once-monthly subcutaneous injection via autoinjector.
Medical Research, Pharmaceuticals
Project
currently has over 20 programs in discovery, with 2 active clinical programs and 2 additional programs expected to enter the clinic within approximately one year, targeting a cadence of 1 to 2 programs advancing into the clinic annually, supported by approximately $700 million in available liquidity.
Research & Development, Business Finance, Clinical Operations, Finance
Project
AbCellera has reported that in patient surveys, over half of women preferred amonthly injectable over a daily oral treatment given equivalent efficacy and safety, with preference exceeding 75% to 80% among those with prior autoinjector experience, and has also identified a potential efficacy differentiation opportunity for ABCL-635 given that fezolinetant's dosing may have been limited by its liver safety signal.
Medical Research, Pharmaceuticals
Project
Sales
AbCellera News & Media
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop Jazz has the exclusive option to develop and commercialize therapeutic antibodies resulting from...7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside PotentialAbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AbCellera Biologics Inc. (ABCL) Bank of America Global Healthcare Conference 2026 May 13, 2026 8:01 PM EDTCompany ParticipantsCarl L.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding AbCellera
Sign Up For FreeTo access detailed company insights
AbCellera is a biotechnology company based in Vancouver, Canada, specializing in antibody discovery and development. Their proprietary technology platform leverages single-cell screening, machine learning, and high-throughput genomics to identify and develop therapeutic antibodies. AbCellera collaborates with pharmaceutical and biotechnology compan... Read More
